Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:CNCENASDAQ:LMNLNASDAQ:UROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$16.89+0.3%$14.85$8.00▼$17.47$1.53B1.561.30 million shs510,834 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/ALMNLLiminal BioSciences$8.50+0.1%$8.47$3.10▼$8.50$26.35M1.0363,470 shs5,000 shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/A7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+0.30%-1.17%+26.90%+19.62%+89.99%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LMNLLiminal BioSciences0.00%0.00%0.00%0.00%+140.79%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals3.7921 of 5 stars4.52.00.00.03.43.30.6CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$22.5733.64% UpsideCNCEConcert PharmaceuticalsN/AN/AN/AN/ALMNLLiminal BioSciences2.00HoldN/AN/AUROVUrovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest UROV, LMNL, AVDL, and CNCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.003/5/2024AVDLAvadel PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $23.003/5/2024AVDLAvadel PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $29.003/5/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.003/5/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.002/6/2024AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M54.72N/AN/A$0.98 per share17.23CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58LMNLLiminal BioSciences$310K85.00N/AN/A$8.97 per share0.95UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A20.35N/AN/A-198.06%-84.51%5/2/2024 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/ALMNLLiminal BioSciences$380K$0.2929.31∞N/A248.35%-88.44%-64.15%N/AUROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest UROV, LMNL, AVDL, and CNCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/ALMNLLiminal BioSciencesN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36CNCEConcert PharmaceuticalsN/A9.039.03LMNLLiminal BioSciences0.022.782.78UROVUrovant SciencesN/A2.912.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CNCEConcert Pharmaceuticals70.63%LMNLLiminal BioSciences0.66%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%CNCEConcert Pharmaceuticals11.33%LMNLLiminal BioSciences2.20%UROVUrovant Sciences2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableLMNLLiminal BioSciences2513.10 million3.04 millionNot OptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableUROV, LMNL, AVDL, and CNCE HeadlinesSourceHeadlineC-Suite Shuffle: A2 Bio, Bayer, BioNTech and Morebiospace.com - March 27 at 2:46 AMA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMHEALTH BEHAVIOR AND NUTRITION SCIENCESudel.edu - February 17 at 2:30 PMBulletin Science and Security Boardthebulletin.org - February 15 at 3:32 PMSecretary-General’s Guidance Note on Behavioural Scienceun.org - February 5 at 9:35 AMMarine Sciences & Technologyuml.edu - January 7 at 12:52 PMThe 7 Best Science Kits for Kids and Teenspopularmechanics.com - December 22 at 12:32 AMCareers in Computer Sciencemccormick.northwestern.edu - December 11 at 10:18 AMPhD in Information Sciencedrexel.edu - December 8 at 10:01 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMCore Requirements & Coursesbc.edu - December 1 at 1:25 PMInspiring Women in Sciencenature.com - November 28 at 10:11 AMDevelop your own cognitive toolkit.miamioh.edu - November 17 at 9:55 AMBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightmedgadget.com - November 16 at 8:17 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis Cmedpagetoday.com - September 26 at 3:23 PMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMClinical and Translational Science Institutebuffalo.edu - September 8 at 9:36 PMMDxHealth CEO Bullish After Q2 Revenue Boostocbj.com - September 5 at 8:49 PMWindmill Model Science Projecteducation.com - August 15 at 1:51 AMTop Science Newssciencedaily.com - August 10 at 1:52 PMAbout This Sitesciencedaily.com - August 5 at 4:13 PMCNVCF - BioHarvest Sciences Inc.finance.yahoo.com - July 31 at 2:30 AMUroGen Pharma Announces the Appointment of James Robinson to its Board of Directorsbusinesswire.com - July 25 at 5:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Liminal BioSciencesNASDAQ:LMNLLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.